Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Slow-tempo low-dose cytarabine + thioguanine for acute myeloid leukemia
ACTRN12617000231347Phase 2Recruiting
- Sponsor
- Northern Sydney Local Health District
- Start
- May 2013
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytarabine, tioguanine and pegfilgrastim in acute myeloid leukemia (AML), sponsored by Northern Sydney Local Health District. Primary endpoint: Complete response rate. Started May 2013; status: recruiting.
02
Drugs
cytarabinetioguaninepegfilgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12617000231347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000231347.